Benefit/Risk Assessment for Breast Cancer Chemoprevention With Raloxifene or Tamoxifen for Women Age 50 Years or Older

PURPOSE: The Study of Tamoxifen and Raloxifene (STAR) demonstrated that raloxifene was as effective as tamoxifen in reducing the risk of invasive breast cancer (IBC) in postmenopausal women and had lower risks of thromboembolic events, endometrial cancer, and cataracts but had a nonstatistically sig...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Freedman, Andrew N., Yu, Binbing, Gail, Mitchell H., Costantino, Joseph P., Graubard, Barry I., Vogel, Victor G., Anderson, Garnet L., McCaskill-Stevens, Worta
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2011
Sujets:
Original Reports
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3107748/
https://ncbi.nlm.nih.gov/pubmed/21537036
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.33.0258
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires